Premium
Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non‐resectable) limit?
Author(s) -
Adam René,
Hoti Emir,
Bredt Luis César
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21727
Subject(s) - medicine , chemotherapy , resection , colorectal cancer , hepatectomy , radiology , neoadjuvant therapy , surgery , general surgery , cancer , breast cancer
Surgical resection offers the best chance for cure in patients with colorectal liver metastases; however, only 15–25% of them can benefit from surgery. To increase resectability a number of strategies have been developed in different fields including chemotherapy, surgery, and radiology. Bringing them together into an integrated framework has expanded the number of patients that can be treated with curative intent. This review focuses on recent oncosurgical changes, their impact, and future directions. J. Surg. Oncol. 2010;102:922–931. © 2010 Wiley‐Liss, Inc.